NEUROTECH INTERNATIONAL LIMITED - Announcements

Market Cap $78.33M Add to my watchlist

Healthcare Medical Devices

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical... Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Combining science, nature and human compassion, Little Green Pharma (ASX:LGP) are committed to improving the quality of life for sufferers of debilitating chronic conditions. NEWS: Little Green Pharma shares surge as Germany legalises Cannabis.

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

NTI	Phase II/III autism trial shows further benefits	PRICE SENSITIVE	18/07/24	194.28KB	Share
NTI	Significant improvement in Autism patients at 12 weeks	PRICE SENSITIVE	10/07/24	347.14KB	Share
NTI	Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment	PRICE SENSITIVE	17/06/24	190.62KB	Share
NTI	Further clinical benefit at 52 weeks in PANDAS/PANS patients	PRICE SENSITIVE	06/06/24	190.18KB	Share
NTI	Rett Syndrome Phase I/II trial shows significant benefits	PRICE SENSITIVE	06/05/24	593.85KB	Share
NTI	Trading Halt	PRICE SENSITIVE	03/05/24	140.26KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	23/04/24	445.81KB	Share
NTI	Neurotech Completes $10 Million Capital Raise	PRICE SENSITIVE	17/04/24	193.4KB	Share
NTI	Positive Top-Line Rett Syndrome Clinical Trial Results	PRICE SENSITIVE	17/04/24	200.12KB	Share
NTI	Phase II/III ASD Trial Successfully Meets Primary Endpoint	PRICE SENSITIVE	17/04/24	361.07KB	Share
NTI	Trading Halt	PRICE SENSITIVE	15/04/24	141.44KB	Share
NTI	Last Patient Completes Treatment in NTIASD2 Clinical Trial	PRICE SENSITIVE	10/04/24	183.31KB	Share
NTI	Rett Syndrome Patients to Receive NTI164 for 52 Weeks	PRICE SENSITIVE	13/03/24	180.94KB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	27/02/24	814.41KB	Share
NTI	PANDAS/PANS Patients Show Continued Clinical Improvement	PRICE SENSITIVE	21/02/24	325.1KB	Share
NTI	Neurotech Receives Additional HREC Approval in Autism	PRICE SENSITIVE	13/02/24	114.1KB	Share
NTI	NTI Receives HREC Approval for Cerebral Palsy Trial	PRICE SENSITIVE	29/01/24	179.92KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/01/24	583.12KB	Share
NTI	Phase II/III Autism Clinical Trial Completes Recruitment	PRICE SENSITIVE	19/12/23	178.77KB	Share
NTI	HREC Approval to Extend Phase II/III ASD Trial to Adults	PRICE SENSITIVE	04/12/23	175.52KB	Share
NTI	Neurotech Receives $3.17 Million R&D Tax Incentive Refund	PRICE SENSITIVE	14/11/23	105.98KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/10/23	396.35KB	Share
NTI	Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint	PRICE SENSITIVE	06/10/23	202.18KB	Share
NTI	Trading Halt	PRICE SENSITIVE	04/10/23	503.7KB	Share
NTI	Completion of Patient Recruitment in NTIRTT1 Clinical Trial	PRICE SENSITIVE	26/09/23	186.34KB	Share
NTI	Last Patient Completes Treatment in NTIPANS1 Clinical Trial	PRICE SENSITIVE	31/08/23	141.88KB	Share
NTI	Appendix 4E & Annual Report	PRICE SENSITIVE	30/08/23	1.16MB	Share
NTI	First Patient Treated in Rett Syndrome Clinical Trial	PRICE SENSITIVE	01/08/23	181.29KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/07/23	321.97KB	Share
NTI	NTI Receives HREC Approval for Rett Syndrome Clinical Trial	PRICE SENSITIVE	10/07/23	213.2KB	Share
NTI	NTI Granted 2 Year Extension of Treatment for ASD Patients	PRICE SENSITIVE	31/05/23	188.33KB	Share
NTI	NTI granted HREC Approval for PANDAS/PANS Trial Extension	PRICE SENSITIVE	30/05/23	178.8KB	Share
NTI	NTI Completes Recruitment in PANDAS/PANS Clinical Trial	PRICE SENSITIVE	03/05/23	138.62KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/04/23	335.94KB	Share
NTI	NTI to Launch Phase II Clinical Trial in Rett Syndrome	PRICE SENSITIVE	20/03/23	199.04KB	Share
NTI	Phase I/II ASD Clinical Trials Results at 52 Weeks	PRICE SENSITIVE	17/03/23	360.83KB	Share
NTI	Trading Halt	PRICE SENSITIVE	15/03/23	499.87KB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	28/02/23	476.67KB	Share
NTI	First Patient Treated in Phase I/II PANDAS/PANS Trial	PRICE SENSITIVE	16/02/23	170.25KB	Share
NTI	Approval for Additional Phase I/II ASD Trial Extension	PRICE SENSITIVE	14/02/23	170.33KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/23	711.15KB	Share
NTI	HREC Approval for Phase I/II PANDAS/PANS Clinical Trial	PRICE SENSITIVE	27/01/23	207.61KB	Share
NTI	NTI Granted FDA Pre-IND Meeting for NTI164 in ASD	PRICE SENSITIVE	19/01/23	173.92KB	Share
NTI	Disclosure Document	PRICE SENSITIVE	22/12/22	303.07KB	Share
NTI	Commencement of Phase II/III ASD Clinical Trial	PRICE SENSITIVE	19/12/22	179.16KB	Share
NTI	NTI Receives HREC/TGA Approval for Phase II/III ASD Trial	PRICE SENSITIVE	17/11/22	271.47KB	Share
NTI	Neurotech Receives $1.2M R&D Tax Rebate	PRICE SENSITIVE	31/10/22	133.45KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	340.9KB	Share
NTI	Reinstatement to Quotation	PRICE SENSITIVE	28/10/22	409.65KB	Share
NTI	Neurotech Completes $9.0M Placement	PRICE SENSITIVE	28/10/22	280.19KB	Share
NTI	Suspension From Official Quotation	PRICE SENSITIVE	27/10/22	585.19KB	Share
NTI	20 Week Data Shows Significant Improvement For ASD Children	PRICE SENSITIVE	26/10/22	465.94KB	Share
NTI	Trading Halt	PRICE SENSITIVE	25/10/22	501.3KB	Share
NTI	New Phase I/II Clinical Trial in Children with PANDAS/PANS	PRICE SENSITIVE	17/10/22	187.64KB	Share
NTI	Executive Change	PRICE SENSITIVE	01/09/22	104.84KB	Share
NTI	Appendix 4E & Annual Report	PRICE SENSITIVE	31/08/22	839KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	337.34KB	Share
NTI	Q&A on NTI164 Breakthrough Clinical Trial Results in ASD	PRICE SENSITIVE	22/07/22	143.91KB	Share
NTI	Reinstatement to Official Quotation	PRICE SENSITIVE	08/07/22	415.41KB	Share
NTI	BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD	PRICE SENSITIVE	08/07/22	333.24KB	Share
NTI	Extension to Voluntary Suspension	PRICE SENSITIVE	07/07/22	66.46KB	Share
NTI	Suspension from Official Quotation	PRICE SENSITIVE	06/07/22	478.53KB	Share
NTI	Trading Halt	PRICE SENSITIVE	04/07/22	468.39KB	Share
NTI	Preclinical Success with Targeted Combination Therapies	PRICE SENSITIVE	09/06/22	211.17KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	264.61KB	Share
NTI	Successful Landmark Study in Paediatric ASD	PRICE SENSITIVE	05/04/22	242.62KB	Share
NTI	Appointment of Chief Executive Officer	PRICE SENSITIVE	03/03/22	155.56KB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	24/02/22	1.64MB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	959.81KB	Share
NTI	Preclinical Success with Targeted Combination Therapies	PRICE SENSITIVE	01/12/21	321.37KB	Share
NTI	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/10/21	1.56MB	Share
NTI	Response to ASX Query Letter	PRICE SENSITIVE	14/10/21	295.41KB	Share
NTI	Provisional Patent Lodgements	PRICE SENSITIVE	14/10/21	124.55KB	Share
NTI	Trading Halt	PRICE SENSITIVE	12/10/21	135.33KB	Share
NTI	Appendix 4E and Annual Report	PRICE SENSITIVE	30/08/21	1.02MB	Share
NTI	Quarterly Report and Appendix 4C	PRICE SENSITIVE	30/07/21	365.86KB	Share
NTI	Quarterly Report and Appendix 4C	PRICE SENSITIVE	03/05/21	295.97KB	Share
NTI	Disclosure Document	PRICE SENSITIVE	15/03/21	401.87KB	Share
NTI	Neurotech Expands License with Dolce Cann Global	PRICE SENSITIVE	02/03/21	82.52KB	Share
NTI	Neurotech Secures $3.56m in Funding	PRICE SENSITIVE	02/03/21	165.7KB	Share
NTI	Appendix 4D and Half Year Accounts	PRICE SENSITIVE	26/02/21	661.89KB	Share
NTI	Trading Halt	PRICE SENSITIVE	26/02/21	173.33KB	Share
NTI	Quarterly Report and Appendix 4C	PRICE SENSITIVE	29/01/21	369.81KB	Share
NTI	Successful Completion of In Vitro Studies	PRICE SENSITIVE	21/12/20	384.21KB	Share
NTI	Disclosure Document	PRICE SENSITIVE	16/12/20	454.41KB	Share
NTI	Reinstatement to Official Quotation	PRICE SENSITIVE	30/11/20	402.35KB	Share
NTI	Further Success with Preliminary In-vitro Studies	PRICE SENSITIVE	30/11/20	128.54KB	Share
NTI	Voluntary Suspension	PRICE SENSITIVE	27/11/20	159.73KB	Share
NTI	Trading Halt	PRICE SENSITIVE	24/11/20	480.17KB	Share
NTI	Disclosure Document	PRICE SENSITIVE	06/11/20	386.42KB	Share
NTI	Interim Results and Capital Raising	PRICE SENSITIVE	02/11/20	103.57KB	Share
NTI	Quarterly Report and Appendix 4C	PRICE SENSITIVE	02/11/20	347.47KB	Share
NTI	Trading Halt	PRICE SENSITIVE	29/10/20	143.63KB	Share
NTI	Response to ASX Price and Volume Query	PRICE SENSITIVE	22/10/20	208.6KB	Share
NTI	Neurotech Proceeds to in vitro trials after Positive Results	PRICE SENSITIVE	07/09/20	472.55KB	Share
NTI	Appendix 4E and Annual Report	PRICE SENSITIVE	31/08/20	718.09KB	Share
NTI	Disclosure Document	PRICE SENSITIVE	26/08/20	422.17KB	Share
NTI	Response to ASX price query	PRICE SENSITIVE	21/08/20	657.35KB	Share
NTI	Pause in Trading	PRICE SENSITIVE	21/08/20	113.83KB	Share
NTI	Promising Early Results from Cannabinoid Analysis	PRICE SENSITIVE	21/08/20	136.93KB	Share

NTI Phase II/III autism trial shows further benefits
18/07/24	PRICE SENSITIVE	194.28KB	Share
NTI Significant improvement in Autism patients at 12 weeks
10/07/24	PRICE SENSITIVE	347.14KB	Share
NTI Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment
17/06/24	PRICE SENSITIVE	190.62KB	Share
NTI Further clinical benefit at 52 weeks in PANDAS/PANS patients
06/06/24	PRICE SENSITIVE	190.18KB	Share
NTI Rett Syndrome Phase I/II trial shows significant benefits
06/05/24	PRICE SENSITIVE	593.85KB	Share
NTI Trading Halt
03/05/24	PRICE SENSITIVE	140.26KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
23/04/24	PRICE SENSITIVE	445.81KB	Share
NTI Neurotech Completes $10 Million Capital Raise
17/04/24	PRICE SENSITIVE	193.4KB	Share
NTI Positive Top-Line Rett Syndrome Clinical Trial Results
17/04/24	PRICE SENSITIVE	200.12KB	Share
NTI Phase II/III ASD Trial Successfully Meets Primary Endpoint
17/04/24	PRICE SENSITIVE	361.07KB	Share
NTI Trading Halt
15/04/24	PRICE SENSITIVE	141.44KB	Share
NTI Last Patient Completes Treatment in NTIASD2 Clinical Trial
10/04/24	PRICE SENSITIVE	183.31KB	Share
NTI Rett Syndrome Patients to Receive NTI164 for 52 Weeks
13/03/24	PRICE SENSITIVE	180.94KB	Share
NTI Appendix 4D and Half Year Accounts
27/02/24	PRICE SENSITIVE	814.41KB	Share
NTI PANDAS/PANS Patients Show Continued Clinical Improvement
21/02/24	PRICE SENSITIVE	325.1KB	Share
NTI Neurotech Receives Additional HREC Approval in Autism
13/02/24	PRICE SENSITIVE	114.1KB	Share
NTI NTI Receives HREC Approval for Cerebral Palsy Trial
29/01/24	PRICE SENSITIVE	179.92KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
24/01/24	PRICE SENSITIVE	583.12KB	Share
NTI Phase II/III Autism Clinical Trial Completes Recruitment
19/12/23	PRICE SENSITIVE	178.77KB	Share
NTI HREC Approval to Extend Phase II/III ASD Trial to Adults
04/12/23	PRICE SENSITIVE	175.52KB	Share
NTI Neurotech Receives $3.17 Million R&D Tax Incentive Refund
14/11/23	PRICE SENSITIVE	105.98KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
27/10/23	PRICE SENSITIVE	396.35KB	Share
NTI Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint
06/10/23	PRICE SENSITIVE	202.18KB	Share
NTI Trading Halt
04/10/23	PRICE SENSITIVE	503.7KB	Share
NTI Completion of Patient Recruitment in NTIRTT1 Clinical Trial
26/09/23	PRICE SENSITIVE	186.34KB	Share
NTI Last Patient Completes Treatment in NTIPANS1 Clinical Trial
31/08/23	PRICE SENSITIVE	141.88KB	Share
NTI Appendix 4E & Annual Report
30/08/23	PRICE SENSITIVE	1.16MB	Share
NTI First Patient Treated in Rett Syndrome Clinical Trial
01/08/23	PRICE SENSITIVE	181.29KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
26/07/23	PRICE SENSITIVE	321.97KB	Share
NTI NTI Receives HREC Approval for Rett Syndrome Clinical Trial
10/07/23	PRICE SENSITIVE	213.2KB	Share
NTI NTI Granted 2 Year Extension of Treatment for ASD Patients
31/05/23	PRICE SENSITIVE	188.33KB	Share
NTI NTI granted HREC Approval for PANDAS/PANS Trial Extension
30/05/23	PRICE SENSITIVE	178.8KB	Share
NTI NTI Completes Recruitment in PANDAS/PANS Clinical Trial
03/05/23	PRICE SENSITIVE	138.62KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
27/04/23	PRICE SENSITIVE	335.94KB	Share
NTI NTI to Launch Phase II Clinical Trial in Rett Syndrome
20/03/23	PRICE SENSITIVE	199.04KB	Share
NTI Phase I/II ASD Clinical Trials Results at 52 Weeks
17/03/23	PRICE SENSITIVE	360.83KB	Share
NTI Trading Halt
15/03/23	PRICE SENSITIVE	499.87KB	Share
NTI Appendix 4D and Half Year Accounts
28/02/23	PRICE SENSITIVE	476.67KB	Share
NTI First Patient Treated in Phase I/II PANDAS/PANS Trial
16/02/23	PRICE SENSITIVE	170.25KB	Share
NTI Approval for Additional Phase I/II ASD Trial Extension
14/02/23	PRICE SENSITIVE	170.33KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
30/01/23	PRICE SENSITIVE	711.15KB	Share
NTI HREC Approval for Phase I/II PANDAS/PANS Clinical Trial
27/01/23	PRICE SENSITIVE	207.61KB	Share
NTI NTI Granted FDA Pre-IND Meeting for NTI164 in ASD
19/01/23	PRICE SENSITIVE	173.92KB	Share
NTI Disclosure Document
22/12/22	PRICE SENSITIVE	303.07KB	Share
NTI Commencement of Phase II/III ASD Clinical Trial
19/12/22	PRICE SENSITIVE	179.16KB	Share
NTI NTI Receives HREC/TGA Approval for Phase II/III ASD Trial
17/11/22	PRICE SENSITIVE	271.47KB	Share
NTI Neurotech Receives $1.2M R&D Tax Rebate
31/10/22	PRICE SENSITIVE	133.45KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	340.9KB	Share
NTI Reinstatement to Quotation
28/10/22	PRICE SENSITIVE	409.65KB	Share
NTI Neurotech Completes $9.0M Placement
28/10/22	PRICE SENSITIVE	280.19KB	Share
NTI Suspension From Official Quotation
27/10/22	PRICE SENSITIVE	585.19KB	Share
NTI 20 Week Data Shows Significant Improvement For ASD Children
26/10/22	PRICE SENSITIVE	465.94KB	Share
NTI Trading Halt
25/10/22	PRICE SENSITIVE	501.3KB	Share
NTI New Phase I/II Clinical Trial in Children with PANDAS/PANS
17/10/22	PRICE SENSITIVE	187.64KB	Share
NTI Executive Change
01/09/22	PRICE SENSITIVE	104.84KB	Share
NTI Appendix 4E & Annual Report
31/08/22	PRICE SENSITIVE	839KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	337.34KB	Share
NTI Q&A on NTI164 Breakthrough Clinical Trial Results in ASD
22/07/22	PRICE SENSITIVE	143.91KB	Share
NTI Reinstatement to Official Quotation
08/07/22	PRICE SENSITIVE	415.41KB	Share
NTI BREAKTHROUGH RESULTS WITH NTI164 IN PAEDIATRIC ASD
08/07/22	PRICE SENSITIVE	333.24KB	Share
NTI Extension to Voluntary Suspension
07/07/22	PRICE SENSITIVE	66.46KB	Share
NTI Suspension from Official Quotation
06/07/22	PRICE SENSITIVE	478.53KB	Share
NTI Trading Halt
04/07/22	PRICE SENSITIVE	468.39KB	Share
NTI Preclinical Success with Targeted Combination Therapies
09/06/22	PRICE SENSITIVE	211.17KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	264.61KB	Share
NTI Successful Landmark Study in Paediatric ASD
05/04/22	PRICE SENSITIVE	242.62KB	Share
NTI Appointment of Chief Executive Officer
03/03/22	PRICE SENSITIVE	155.56KB	Share
NTI Appendix 4D and Half Year Accounts
24/02/22	PRICE SENSITIVE	1.64MB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	959.81KB	Share
NTI Preclinical Success with Targeted Combination Therapies
01/12/21	PRICE SENSITIVE	321.37KB	Share
NTI Quarterly Activities/Appendix 4C Cash Flow Report
29/10/21	PRICE SENSITIVE	1.56MB	Share
NTI Response to ASX Query Letter
14/10/21	PRICE SENSITIVE	295.41KB	Share
NTI Provisional Patent Lodgements
14/10/21	PRICE SENSITIVE	124.55KB	Share
NTI Trading Halt
12/10/21	PRICE SENSITIVE	135.33KB	Share
NTI Appendix 4E and Annual Report
30/08/21	PRICE SENSITIVE	1.02MB	Share
NTI Quarterly Report and Appendix 4C
30/07/21	PRICE SENSITIVE	365.86KB	Share
NTI Quarterly Report and Appendix 4C
03/05/21	PRICE SENSITIVE	295.97KB	Share
NTI Disclosure Document
15/03/21	PRICE SENSITIVE	401.87KB	Share
NTI Neurotech Expands License with Dolce Cann Global
02/03/21	PRICE SENSITIVE	82.52KB	Share
NTI Neurotech Secures $3.56m in Funding
02/03/21	PRICE SENSITIVE	165.7KB	Share
NTI Appendix 4D and Half Year Accounts
26/02/21	PRICE SENSITIVE	661.89KB	Share
NTI Trading Halt
26/02/21	PRICE SENSITIVE	173.33KB	Share
NTI Quarterly Report and Appendix 4C
29/01/21	PRICE SENSITIVE	369.81KB	Share
NTI Successful Completion of In Vitro Studies
21/12/20	PRICE SENSITIVE	384.21KB	Share
NTI Disclosure Document
16/12/20	PRICE SENSITIVE	454.41KB	Share
NTI Reinstatement to Official Quotation
30/11/20	PRICE SENSITIVE	402.35KB	Share
NTI Further Success with Preliminary In-vitro Studies
30/11/20	PRICE SENSITIVE	128.54KB	Share
NTI Voluntary Suspension
27/11/20	PRICE SENSITIVE	159.73KB	Share
NTI Trading Halt
24/11/20	PRICE SENSITIVE	480.17KB	Share
NTI Disclosure Document
06/11/20	PRICE SENSITIVE	386.42KB	Share
NTI Interim Results and Capital Raising
02/11/20	PRICE SENSITIVE	103.57KB	Share
NTI Quarterly Report and Appendix 4C
02/11/20	PRICE SENSITIVE	347.47KB	Share
NTI Trading Halt
29/10/20	PRICE SENSITIVE	143.63KB	Share
NTI Response to ASX Price and Volume Query
22/10/20	PRICE SENSITIVE	208.6KB	Share
NTI Neurotech Proceeds to in vitro trials after Positive Results
07/09/20	PRICE SENSITIVE	472.55KB	Share
NTI Appendix 4E and Annual Report
31/08/20	PRICE SENSITIVE	718.09KB	Share
NTI Disclosure Document
26/08/20	PRICE SENSITIVE	422.17KB	Share
NTI Response to ASX price query
21/08/20	PRICE SENSITIVE	657.35KB	Share
NTI Pause in Trading
21/08/20	PRICE SENSITIVE	113.83KB	Share
NTI Promising Early Results from Cannabinoid Analysis
21/08/20	PRICE SENSITIVE	136.93KB	Share

REFRESH

(20min delay)
Last 7.7¢		Change -0.001(1.28%)		Mkt cap ! $78.33M

Open	High	Low	Value	Volume
7.9¢	8.1¢	7.7¢	$54.26K	684.2K

Buyers (Bids)

No.	Vol.	Price($)
3	98220	7.7¢

Sellers (Offers)

Price($)	Vol.	No.
7.9¢	21369	1

View Market Depth

No.	Vol.	Price($)
3	98220	0.077
2	107894	0.076
3	263338	0.075
1	160000	0.074
3	149500	0.073

Price($)	Vol.	No.
0.079	21369	1
0.080	344270	2
0.081	40000	2
0.082	85000	1
0.086	100000	2

Last trade - 15.59pm 22/07/2024 (20 minute delay)


Last 7.7¢		Change -0.001 ( 2.53 %)
Open	High	Low	Volume
7.8¢	8.1¢	7.7¢	203193
Last updated 15.59pm 22/07/2024 ?

NTI (ASX) Chart

NEUROTECH INTERNATIONAL LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories